FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+42.11%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.37B
AUM Growth
+$2.37B
(+27%)
Cap. Flow
+$123M
Cap. Flow
% of AUM
5.2%
Top 10 Holdings %
Top 10 Hldgs %
58.56%
Holding
56
New
7
Increased
13
Reduced
6
Closed
6
Top Buys
| 1 |
CG Oncology
CGON
|
$33.8M |
| 2 |
Oric Pharmaceuticals
ORIC
|
$27.5M |
| 3 |
PepGen
PEPG
|
$22.1M |
| 4 |
BridgeBio Pharma
BBIO
|
$21.3M |
| 5 |
Soleno Therapeutics
SLNO
|
$17.6M |
Top Sells
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$16.1M |
| 2 |
Dyne Therapeutics
DYN
|
$15.8M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$14.1M |
| 4 |
89bio
ETNB
|
$11.6M |
| 5 |
Apogee Therapeutics
APGE
|
$11.2M |
Sector Composition
| 1 | Healthcare | 99.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
NewAmsterdam Pharma
NAMS
$2.71B
| $289M | 12.2% | 12,226,943 +95,238 | +0.8% | +$2.25M |
|
2
Krystal Biotech
KRYS
$4.27B
| $176M | 7.42% | 988,460 | – | – |
|
3
Mirum Pharmaceuticals
MIRM
$3.71B
| $163M | 6.88% | 6,495,392 | – | – |
|
4
HilleVax
HLVX
$105M
| $163M | 6.86% | 9,781,472 | – | – |
|
|
ALPN
5
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $124M | 5.24% | 3,131,008 | – | – |
|
6
Phathom Pharmaceuticals
PHAT
$864M
| $107M | 4.53% | 10,109,279 | – | – |
|
|
7
BridgeBio Pharma
BBIO
$9.89B
| $106M | 4.46% | 3,415,604 +689,655 | +25% | +$21.3M |
|
8
Rhythm Pharmaceuticals
RYTM
$6.85B
| $94.9M | 4% | 2,190,179 -181,125 | -8% | -$7.85M |
|
9
Arcutis Biotherapeutics
ARQT
$1.86B
| $87.1M | 3.67% | 8,785,284 +21,052 | +0.2% | +$209K |
|
10
Vaxcyte
PCVX
$4B
| $77.8M | 3.28% | 1,139,405 -25,000 | -2% | -$1.71M |
|
11
Tarsus Pharmaceuticals
TARS
$2.47B
| $65M | 2.74% | 1,787,527 | – | – |
|
12
Edgewise Therapeutics
EWTX
$1.51B
| $60.3M | 2.54% | 3,303,567 +636,364 | +24% | +$11.6M |
|
|
13
Oric Pharmaceuticals
ORIC
$994M
| $57M | 2.4% | 4,142,855 +2,000,000 | +93% | +$27.5M |
|
14
Apellis Pharmaceuticals
APLS
$3.48B
| $52M | 2.2% | 885,165 | – | – |
|
15
Disc Medicine
IRON
$2.07B
| $48.9M | 2.06% | 785,000 | – | – |
|
|
VRNA
16
Verona Pharma
VRNA
$9.16B
| $48.5M | 2.05% | 3,014,349 | – | – |
|
17
KalVista Pharmaceuticals
KALV
$678M
| $43.7M | 1.85% | 3,687,867 +65,573 | +2% | +$778K |
|
18
Rocket Pharmaceuticals
RCKT
$354M
| $42.1M | 1.77% | 1,561,230 +38,217 | +3% | +$1.03M |
|
|
19
Soleno Therapeutics
SLNO
$3.6B
| $37.5M | 1.58% | 875,667 +410,730 | +88% | +$17.6M |
|
20
MacroGenics
MGNX
$112M
| $36.4M | 1.54% | 2,471,704 +70,000 | +3% | +$1.03M |
|
|
JBIO
21
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $35.6M | 1.5% | 1,204,867 | – | – |
|
|
22
CG Oncology
CGON
$2.04B
| $33.8M | 1.43% | +770,000 | New | +$33.8M |
|
23
Merus
MRUS
$4.98B
| $33.6M | 1.42% | 746,479 | – | – |
|
24
Revolution Medicines
RVMD
$7.1B
| $32.1M | 1.36% | 997,455 | – | – |
|
|
AUTL
25
Autolus Therapeutics
AUTL
$399M
| $29.5M | 1.24% | 4,623,324 +876,467 | +23% | +$5.59M |
|